Chronic Inflammatory Demyelinating Polyneuropathy
Market Analysis, Epidemiology and Market Forecast to 2030

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves.

Although CIDP can occur at any age and in both genders, it is more common in men than women and the highest number of people affected with CIDP are found in the age-group of 65 and above years.

Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis
The Chronic Inflammatory Demyelinating Polyneuropathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Inflammatory Demyelinating Polyneuropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The market segment gives a thorough detail of Chronic Inflammatory Demyelinating Polyneuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
For more details visit:
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market